Manabu Soda

Title: Manabu Soda: Innovator in Cancer Research

Introduction

Manabu Soda is a prominent inventor based in Tochigi, Japan. He has made significant contributions to the field of cancer research, particularly in the detection and treatment of cancers associated with specific genetic mutations. With a total of 2 patents, his work has the potential to impact cancer diagnostics and therapy.

Latest Patents

Soda's latest patents include a detection method for novel ROS1 fusions. This invention elucidates polynucleotides that are novel causative genes for cancer. The detection method involves identifying a fusion gene that comprises parts of specific genes, such as SDC4, CD74, EZR, SLC34A2, LRIG3, or TPM3, along with a ROS1 gene. Additionally, he has developed a kit and a primer set for detection based on this knowledge. Another significant patent focuses on the identification, assessment, and therapy of cancers with innate or acquired resistance to ALK inhibitors. This patent describes methods for determining the likelihood of response to ALK inhibitors in patients with ALK mutations, as well as prognostic methods for disease progression.

Career Highlights

Throughout his career, Manabu Soda has worked with notable organizations, including the Japanese Foundation for Cancer Research and Jichi Medical University. His research has been instrumental in advancing the understanding of cancer genetics and treatment options.

Collaborations

Soda has collaborated with esteemed colleagues such as Hiroyuki Mano and Kengo Takeuchi. Their combined expertise has contributed to the development of innovative solutions in cancer research.

Conclusion

Manabu Soda's contributions to cancer research through his patents and collaborations highlight his role as a key innovator in the field. His work continues to pave the way for advancements in cancer detection and treatment.